-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Entritinib's overall efficacy (ORR of 67.
The Journal of Clinical Oncology yesterday released the latest updates of three phase I or phase II clinical trials (ALKA-372-001, STARTRK-1 and STARTRK-2) of Entratinib in ROS1 fusion-positive non-small cell lung cancer ( NSCLC ) Comprehensive analysis results.
NSCLC
The gene rearrangement of the tyrosine receptor kinase ROS proto-oncogene 1 (ROS1) is a carcinogenic driver of non-small cell lung cancer (NSCLC).
Therefore, researchers have a new idea to extend the follow-up time and confirm in a larger population that Entratinib can be used in patients with locally advanced or metastatic ROS proto-oncogene 1 (ROS1) fusion-positive non-small cell lung cancer (including baseline The effectiveness and safety of patients with central transfer?
This study included adult patients with locally advanced or metastatic ROS1 fusion-positive NSCLC, with or without CNS metastasis.
In the population with a follow-up longer than 6 months and comprehensive efficacy evaluation (n = 161), STARTRK-2 was enrolled in 145 cases, STARTRK-1 was enrolled in 7 cases, and ALKA-372-001 was enrolled in 9 cases.
Through BICR assessment, the target lesions of most patients became smaller, and a clear objective remission was achieved in 108 patients (67.
The ORR was 67.
The ORR was 67.
The intracranial ORR of 24 patients with CNS metastasis was 79.
According to the investigator's assessment, after BICR scans were performed on the scan results of patients with central nervous system diseases at baseline, 46 patients with central nervous system metastases were confirmed.
Among the 24 patients with measurable CNS metastases at baseline, the intracranial ORR was 79.
Among the 24 patients with measurable CNS metastases at baseline, the intracranial ORR was 79.
The security situation is consistent with the previous report.
Most AEs are low-grade, manageable , and comparable to other ROS1 inhibitors.
Entratinib continues to show a high degree of clinical benefit in patients with ROS1 fusion-positive NSCLC, especially in patients with CNS metastases.
Rafal Dziadziuszko, Matthew G.
org/doi/abs/10.
1200/JCO.
20.
03025">Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
DOI: 10.
1200/JCO.
20.
03025
Leave a message here
